Treatment of hypoparathyroidism

F Tecilazich; AM Formenti; S Frara; Raffaele Giubbini; A Giustina

doi:10.1016/j.beem.2018.12.002

Treatment of hypoparathyroidism

F Tecilazich, AM Formenti, S Frara, Raffaele Giubbini, A Giustina

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1–84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1–84) appears to represent a new option in patients with chronic hypoparathyroidism “resistant” to conventional treatment. © 2018

Original language	English
Pages (from-to)	955-964
Number of pages	10
Journal	Best Practice and Research: Clinical Endocrinology and Metabolism
Volume	32
Issue number	6
DOIs	https://doi.org/10.1016/j.beem.2018.12.002
Publication status	Published - 2018

Access to Document

10.1016/j.beem.2018.12.002

http://www.scopus.com/inward/record.url?scp=85058138195&partnerID=8YFLogxK

Cite this

@article{a12b1e70ea2d4e40b1e74b7adbb0d9b8,

title = "Treatment of hypoparathyroidism",

abstract = "The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1–84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1–84) appears to represent a new option in patients with chronic hypoparathyroidism “resistant” to conventional treatment. {\textcopyright} 2018",

author = "F Tecilazich and AM Formenti and S Frara and Raffaele Giubbini and A Giustina",

year = "2018",

doi = "10.1016/j.beem.2018.12.002",

language = "English",

volume = "32",

pages = "955--964",

journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",

issn = "1521-690X",

publisher = "Bailliere Tindall Ltd",

number = "6",

}

TY - JOUR

T1 - Treatment of hypoparathyroidism

AU - Tecilazich, F

AU - Formenti, AM

AU - Frara, S

AU - Giubbini, Raffaele

AU - Giustina, A

PY - 2018

Y1 - 2018

N2 - The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1–84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1–84) appears to represent a new option in patients with chronic hypoparathyroidism “resistant” to conventional treatment. © 2018

AB - The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1–84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1–84) appears to represent a new option in patients with chronic hypoparathyroidism “resistant” to conventional treatment. © 2018

U2 - 10.1016/j.beem.2018.12.002

DO - 10.1016/j.beem.2018.12.002

M3 - Article

VL - 32

SP - 955

EP - 964

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 6

ER -

Treatment of hypoparathyroidism

Abstract

Access to Document

Fingerprint

Cite this